One Size Dose Doesn't Fit All


San Francisco - Results from premarketing clinical trials indicate that the usual efalizumab (Raptiva) dosage for the treatment of psoriasis will involve ongoing therapy with 1 mg/kg in the vast majority of patients, but alternate dosing regimens for fine-tuning management may benefit certain subgroups of patients, Kim A. Papp, M.D., said at the annual meeting of the American Academy of Dermatology.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.